Iloperidone Phase III Clinical Data Demonstrate Efficacy and Favorable Safety and Tolerability Profile

News   Dec 14, 2007

 
Iloperidone Phase III Clinical Data Demonstrate Efficacy and Favorable Safety and Tolerability Profile
 
 
 

RELATED ARTICLES

Lab Innovations 2018 – Registration Opens and Keynotes Announced

News

Learn and earn CPD points at the UK’s only lab-dedicated showcase and scientific seminar series.

READ MORE

Anti-TNF Drug Offers Hope to Patients with Disabling Hand Condition

News

Scientists have found that injection of the anti-TNF drug adalimumab into Dupuytren's disease nodules results in the reduction of the cell characteristics responsible for progression of Dupuytren's disease.

READ MORE

A Way to Make Drugs Without Side Effects?

News

A new technique for precisely targeting molecules within cells is paving the way for safer medicines that are free of side effects.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE
 

We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy